Cargando…
COVID-19 at a Glance: An Up-to-Date Overview on Variants, Drug Design and Therapies
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a member of the Coronavirus family which caused the worldwide pandemic of human respiratory illness coronavirus disease 2019 (COVID-19). Presumably emerging at the end of 2019, it poses a severe threat to public health and safety, with...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950852/ https://www.ncbi.nlm.nih.gov/pubmed/35336980 http://dx.doi.org/10.3390/v14030573 |
_version_ | 1784675242228056064 |
---|---|
author | Iacopetta, Domenico Ceramella, Jessica Catalano, Alessia Saturnino, Carmela Pellegrino, Michele Mariconda, Annaluisa Longo, Pasquale Sinicropi, Maria Stefania Aquaro, Stefano |
author_facet | Iacopetta, Domenico Ceramella, Jessica Catalano, Alessia Saturnino, Carmela Pellegrino, Michele Mariconda, Annaluisa Longo, Pasquale Sinicropi, Maria Stefania Aquaro, Stefano |
author_sort | Iacopetta, Domenico |
collection | PubMed |
description | Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a member of the Coronavirus family which caused the worldwide pandemic of human respiratory illness coronavirus disease 2019 (COVID-19). Presumably emerging at the end of 2019, it poses a severe threat to public health and safety, with a high incidence of transmission, predominately through aerosols and/or direct contact with infected surfaces. In 2020, the search for vaccines began, leading to the obtaining of, to date, about twenty COVID-19 vaccines approved for use in at least one country. However, COVID-19 continues to spread and new genetic mutations and variants have been discovered, requiring pharmacological treatments. The most common therapies for COVID-19 are represented by antiviral and antimalarial agents, antibiotics, immunomodulators, angiotensin II receptor blockers, bradykinin B2 receptor antagonists and corticosteroids. In addition, nutraceuticals, vitamins D and C, omega-3 fatty acids and probiotics are under study. Finally, drug repositioning, which concerns the investigation of existing drugs for new therapeutic target indications, has been widely proposed in the literature for COVID-19 therapies. Considering the importance of this ongoing global public health emergency, this review aims to offer a synthetic up-to-date overview regarding diagnoses, variants and vaccines for COVID-19, with particular attention paid to the adopted treatments. |
format | Online Article Text |
id | pubmed-8950852 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89508522022-03-26 COVID-19 at a Glance: An Up-to-Date Overview on Variants, Drug Design and Therapies Iacopetta, Domenico Ceramella, Jessica Catalano, Alessia Saturnino, Carmela Pellegrino, Michele Mariconda, Annaluisa Longo, Pasquale Sinicropi, Maria Stefania Aquaro, Stefano Viruses Review Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a member of the Coronavirus family which caused the worldwide pandemic of human respiratory illness coronavirus disease 2019 (COVID-19). Presumably emerging at the end of 2019, it poses a severe threat to public health and safety, with a high incidence of transmission, predominately through aerosols and/or direct contact with infected surfaces. In 2020, the search for vaccines began, leading to the obtaining of, to date, about twenty COVID-19 vaccines approved for use in at least one country. However, COVID-19 continues to spread and new genetic mutations and variants have been discovered, requiring pharmacological treatments. The most common therapies for COVID-19 are represented by antiviral and antimalarial agents, antibiotics, immunomodulators, angiotensin II receptor blockers, bradykinin B2 receptor antagonists and corticosteroids. In addition, nutraceuticals, vitamins D and C, omega-3 fatty acids and probiotics are under study. Finally, drug repositioning, which concerns the investigation of existing drugs for new therapeutic target indications, has been widely proposed in the literature for COVID-19 therapies. Considering the importance of this ongoing global public health emergency, this review aims to offer a synthetic up-to-date overview regarding diagnoses, variants and vaccines for COVID-19, with particular attention paid to the adopted treatments. MDPI 2022-03-10 /pmc/articles/PMC8950852/ /pubmed/35336980 http://dx.doi.org/10.3390/v14030573 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Iacopetta, Domenico Ceramella, Jessica Catalano, Alessia Saturnino, Carmela Pellegrino, Michele Mariconda, Annaluisa Longo, Pasquale Sinicropi, Maria Stefania Aquaro, Stefano COVID-19 at a Glance: An Up-to-Date Overview on Variants, Drug Design and Therapies |
title | COVID-19 at a Glance: An Up-to-Date Overview on Variants, Drug Design and Therapies |
title_full | COVID-19 at a Glance: An Up-to-Date Overview on Variants, Drug Design and Therapies |
title_fullStr | COVID-19 at a Glance: An Up-to-Date Overview on Variants, Drug Design and Therapies |
title_full_unstemmed | COVID-19 at a Glance: An Up-to-Date Overview on Variants, Drug Design and Therapies |
title_short | COVID-19 at a Glance: An Up-to-Date Overview on Variants, Drug Design and Therapies |
title_sort | covid-19 at a glance: an up-to-date overview on variants, drug design and therapies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950852/ https://www.ncbi.nlm.nih.gov/pubmed/35336980 http://dx.doi.org/10.3390/v14030573 |
work_keys_str_mv | AT iacopettadomenico covid19ataglanceanuptodateoverviewonvariantsdrugdesignandtherapies AT ceramellajessica covid19ataglanceanuptodateoverviewonvariantsdrugdesignandtherapies AT catalanoalessia covid19ataglanceanuptodateoverviewonvariantsdrugdesignandtherapies AT saturninocarmela covid19ataglanceanuptodateoverviewonvariantsdrugdesignandtherapies AT pellegrinomichele covid19ataglanceanuptodateoverviewonvariantsdrugdesignandtherapies AT maricondaannaluisa covid19ataglanceanuptodateoverviewonvariantsdrugdesignandtherapies AT longopasquale covid19ataglanceanuptodateoverviewonvariantsdrugdesignandtherapies AT sinicropimariastefania covid19ataglanceanuptodateoverviewonvariantsdrugdesignandtherapies AT aquarostefano covid19ataglanceanuptodateoverviewonvariantsdrugdesignandtherapies |